The standard treatment for advanced metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). And even if this is efficient in the short term, 1/3 of PCa will become resistant to ADT and develop castration-resistant ...
Mar 29, 2021
0
88
Studying the cellular metabolism of prostate cancer, a team of Duke Health-led researchers identified a key reason hormone therapies eventually fail, while also laying out a way to bypass the problem using an entirely new ...
Mar 22, 2021
0
218
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase ...
Sep 29, 2020
0
9
(HealthDay)—For men with nonmetastatic, castration-resistant prostate cancer, the risk for death is significantly lower for those receiving darolutamide versus placebo, according to a study published in the Sept. 10 issue ...
Sep 15, 2020
0
3
Researchers from Boston University School of Medicine (BUSM) have discovered that the protein BRD4 could be an important new target to prevent castration-resistant prostate cancer metastases.
Jul 21, 2020
0
163
(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...
May 29, 2020
0
5
A transcription factor that aids neuron function also appears to enable a cell conversion in the prostate gland that can make an already recurrent cancer even more deadly, scientists say.
Nov 13, 2019
0
23
Prostate cancer, the second leading cause of cancer-related death for men in the United States, is poorly responsive to immunotherapy. Recent clinical trials have hinted that combining immunotherapy and radiation therapy ...
Aug 26, 2019
0
2
A study led by scientists at the Institute for Research in Biomedicine (IRB Barcelona) and published in Nature Communications proposes chaperone protein Hps70 as an attractive therapeutic target for the treatment of Kennedy's ...
Aug 8, 2019
0
15
Wilmot Cancer Institute scientists believe they have figured out why a commonly used drug to treat late-stage prostate cancer often stops working after four or five months and appears to have a dual function that later turns ...
Jun 13, 2019
0
48
